Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 12, 2019 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Appointment of Veteran Industry Executive Birgitte Volck, M.D., Ph.D., to Board of Directors

REDWOOD CITY, Calif., June 12, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
May 13, 2019 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2019 Financial Results

REDWOOD CITY, Calif., May 13, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
April 29, 2019 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces Appointment of Industry Veteran Gwen A. Melincoff to Board of Directors

REDWOOD CITY, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
April 03, 2019 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

REDWOOD CITY, Calif., April 03, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
March 25, 2019 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics to Participate in the ROTH Battle of NASH Thrones Spring Investor Conference

REDWOOD CITY, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
March 18, 2019 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results

REDWOOD CITY, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
March 11, 2019 16:05 ET | Source: Soleno Therapeutics

Soleno Therapeutics to Participate in Two Upcoming Investor Conferences

REDWOOD CITY, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
December 19, 2018 16:01 ET | Source: Soleno Therapeutics

Soleno Therapeutics Announces $16.5 Million Private Placement

Financing Led by Abingworth; Andrew Sinclair, Partner, to Join Soleno’s Board Funding to Support Ongoing Phase III Clinical Program (DESTINY PWS) for DCCR in Prader-Willi Syndrome REDWOOD CITY,...
November 15, 2018 08:05 ET | Source: Soleno Therapeutics

Soleno Therapeutics Presents Clinical Fat Loss Data on DCCR at the Obesity Society Meeting 2018

DCCR treatment resulted in statistically significant decreases in body fat in subjects with Prader-Willi Syndrome REDWOOD CITY, Calif., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc....
November 15, 2018 08:00 ET | Source: Soleno Therapeutics

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results

REDWOOD CITY, Calif., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...